gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 08 Dec 2016.

C-ros oncogene 1 , receptor tyrosine kinase

Ros, ROS1
This proto-oncogene, highly-expressed in a variety of tumor cell lines, belongs to the sevenless subfamily of tyrosine kinase insulin receptor genes. The protein encoded by this gene is a type I integral membrane protein with tyrosine kinase activity. The protein may function as a growth or differentiation factor receptor. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: ALK, EGFR, RET, KRAS, CAN
Papers on Ros
ROS1 copy number alterations are frequent in non-small cell lung cancer.
New
Salido et al., Barcelona, Spain. In Oncotarget, Feb 2016
OBJECTIVES: We aimed to determine the prevalence and partners of ROS1 rearrangements, to explore the correlation between FISH and IHC assays, and to investigate clinical implications of ROS1 copy number alterations (CNAs).
[Strategy for molecular testing in pulmonary carcinoma].
New
Cayre et al., Clermont-Ferrand, France. In Ann Pathol, Feb 2016
Then, the emerging biomarkers (HER2, ROS1, RET, BRAF…) as well as potentially other markers in case of clinical trials, can been tested.
[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].
New
Wislez et al., Paris, France. In Ann Pathol, Feb 2016
INCA supports ACSé program evaluating the efficacy of crizotinib in NSCLC amplified for MET or translocated for ROS1 and ACSé program evaluating the efficacy of vemurafenib in tumors non melanoma mutated V600E BRAF.
ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.
Review
New
Planchard et al., Villejuif, France. In Ther Adv Med Oncol, Jan 2016
The treatment of patients with advanced non-small cell lung cancer (NSCLC) harbouring chromosomal rearrangements of ALK (anaplastic lymphoma kinase) was revolutionized by crizotinib, a small molecule inhibitor of ALK, ROS1 and MET.
Gene fusions in soft tissue tumors: Recurrent and overlapping pathogenetic themes.
Review
New
Mitelman et al., Lund, Sweden. In Genes Chromosomes Cancer, Jan 2016
Indeed, pharmacological treatment of STT displaying fusions that activate protein kinases, such as ALK and ROS1, or growth factors, such as PDGFB, is already in clinical use.
Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features.
New
Zhou et al., Shanghai, China. In Onco Targets Ther, Dec 2015
OBJECTIVE: To detect ROS1 rearrangement using three different assays, including immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and reverse transcription polymerase chain reaction (RT-PCR), and to analyze the clinicopathologic features of ROS1 rearrangement in patients with lung adenocarcinoma.
Emerging Biomarkers in Personalized Therapy of Lung Cancer.
Review
New
Portier et al., Houston, United States. In Adv Exp Med Biol, Dec 2015
Oncologists are requesting testing for ROS1 translocations which predict susceptibility to crizotinib, already approved for ALK positive lung cancers.
Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer.
Review
New
Shirai et al., Orange, United States. In Adv Exp Med Biol, Dec 2015
A multi-targeted ALK/ROS1/MET inhibitor, crizotinib, targeting this activated tyrosine kinase has led to significant clinical benefit including tumor shrinkage and prolonged survival without disease progression and has been approved by US FDA since 2011 for the treatment of advanced ALK-rearranged NSCLC (Ou et al.
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
New
Impact
Johnson et al., Newark, United States. In J Clin Oncol, Nov 2015
Recommendations for patients in the first-line setting include platinum-doublet therapy for those with PS 0 to 1 (bevacizumab may be added to carboplatin plus paclitaxel if no contraindications); combination or single-agent chemotherapy or palliative care alone for those with PS 2; afatinib, erlotinib, or gefitinib for those with sensitizing EGFR mutations; crizotinib for those with ALK or ROS1 gene rearrangement; and following first-line recommendations or using platinum plus etoposide for those with large-cell neuroendocrine carcinoma.
Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies.
Review
New
Heinzerling et al., Philadelphia, United States. In Transl Lung Cancer Res, Oct 2015
Targeted therapies directed against epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) translocations, and ROS-1 rearrangements have demonstrated improved progression free survival (PFS) and, in selected populations, improved overall survival (OS) compared with cytotoxic chemotherapy.
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.
New
Impact
Smeal et al., San Diego, United States. In Cancer Cell, Aug 2015
We report the preclinical evaluation of PF-06463922, a potent and brain-penetrant ALK/ROS1 inhibitor.
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.
New
Impact
European T-Cell Lymphoma Study Group et al., Torino, Italy. In Cancer Cell, May 2015
Recurrent chimeras combining a transcription factor (NFkB2 or NCOR2) with a tyrosine kinase (ROS1 or TYK2) were also discovered in WT JAK1/STAT3 ALK(-) ALCL.
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
New
Impact
Gautschi et al., Caen, France. In J Clin Oncol, Apr 2015
PURPOSE: Approximately 1% of lung adenocarcinomas are driven by oncogenic ROS1 rearrangement.
Anchored multiplex PCR for targeted next-generation sequencing.
Impact
Le et al., Boston, United States. In Nat Med, 2014
On the basis of our experience with performing AMP on 986 clinical FFPE samples, we show its potential as both a robust clinical assay and a powerful discovery tool, which we used to identify new therapeutically important gene fusions: ARHGEF2-NTRK1 and CHTOP-NTRK1 in glioblastoma, MSN-ROS1, TRIM4-BRAF, VAMP2-NRG1, TPM3-NTRK1 and RUFY2-RET in lung cancer, FGFR2-CREB5 in cholangiocarcinoma and PPL-NTRK1 in thyroid carcinoma.
ROS1 mutation and treatment with crizotinib in a 30-year old Caucasian woman with stage IV non-small cell lung cancer/adenocarcinoma and complete remission.
Studnicka et al., Salzburg, Austria. In Thorac Cancer, 2014
In this case report we describe a 30 year-old Caucasian woman with a histopathological diagnosis of pulmonary adenocarcinoma in both lungs with lipidic and micropapillary growth pattern and ROS1 (C-ros oncogene 1, receptor tyrosine kinase) rearrangement.
The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation.
GeneRIF
Charest et al., Boston, United States. In Cancer Res, 2012
Expression of CD74-ROS in noninvasive NSCLC cell lines readily conferred invasive properties that paralleled the acquisition of E-Syt1 phosphorylation.
Antisilencing role of the RNA-directed DNA methylation pathway and a histone acetyltransferase in Arabidopsis.
GeneRIF
Gong et al., Beijing, China. In Proc Natl Acad Sci U S A, 2012
the Arabidopsis RdDM pathway has an antisilencing function due to its role in maintaining ROS1 expression
Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
GeneRIF
Costa et al., Boston, United States. In J Thorac Oncol, 2012
ROS1 translocation is associated with lung cancer.
ROS1 rearrangements define a unique molecular class of lung cancers.
Impact
GeneRIF
Iafrate et al., Boston, United States. In J Clin Oncol, 2012
ROS1 rearrangement defines a molecular subset of NSCLC with distinct clinical characteristics that are similar to those observed in patients with ALK-rearranged NSCLC.
RET, ROS1 and ALK fusions in lung cancer.
Impact
GeneRIF
Ishikawa et al., Tokyo, Japan. In Nat Med, 2012
we discovered previously unidentified kinase fusions that may be promising for molecular-targeted therapy, kinesin family member 5B (KIF5B)-ret proto-oncogene (RET) and coiled-coil domain containing 6 (CCDC6)-RET, in 14 adenocarcinomas
share on facebooktweetadd +1mail to friends